Longevity Medicine
What Is Longevity Medicine for Women?
Last reviewed: May 2026 · Haute MD Editorial Team
Longevity medicine for women applies the standard longevity framework — biomarkers, exercise, nutrition, sleep, and cognitive health — while addressing sex-specific physiology including the menstrual cycle, perimenopause and menopause, hormonal transitions, accelerated bone loss, and a distinct cardiovascular risk trajectory. It corrects for decades of underrepresentation of women in cardiovascular and longevity research.
Sex-specific physiology that matters
Women have a different cardiovascular risk trajectory — lower premenopausal risk that converges with men's after menopause, partly mediated by loss of estrogen-driven vascular protection. Heart attack symptoms in women are more often atypical (fatigue, jaw or back pain, nausea), contributing to delayed diagnosis and worse outcomes. Bone mineral density peaks in the late 20s and declines slowly until perimenopause, then accelerates dramatically (2-3% per year for 5-7 years post-menopause), substantially elevating osteoporotic fracture risk. Cancer risks differ — breast, ovarian, endometrial, and cervical cancers are female-predominant. Autoimmune disease prevalence is higher in women. Sleep architecture and metabolic responses differ across the menstrual cycle. Pregnancy history (preeclampsia, gestational diabetes, preterm birth) is a strong but underused cardiovascular risk marker.
Perimenopause and menopause
Perimenopause typically begins in the 40s and lasts 4-10 years before menstruation ceases (average menopause age 51 in the U.S.). Symptoms — vasomotor (hot flashes, night sweats), sleep disruption, mood changes, cognitive fog, vaginal dryness, weight redistribution — are driven by erratic and then declining estrogen, progesterone, and testosterone. Long-term consequences include accelerated bone loss, increased cardiovascular risk, urogenital atrophy, and increased visceral fat. Modern menopausal hormone therapy (MHT), when initiated within 10 years of menopause or before age 60 in appropriate candidates, has favorable risk-benefit for symptom control and offers cardiovascular and bone benefit. The 2002 Women's Health Initiative findings have been substantially reinterpreted — older initiation and oral conjugated equine estrogens drove the risk signal; transdermal estradiol with micronized progesterone in younger women has a markedly different profile.
A longevity framework for women
(1) Comprehensive biomarker panel including ApoB, Lp(a), HbA1c, hs-CRP, fasting insulin, thyroid, vitamin D, ferritin, B12, and complete hormone panel appropriate to life stage; (2) Cardiovascular risk assessment using sex-specific calculators that incorporate pregnancy complications; consider coronary artery calcium scoring at 40-50 in higher-risk women; (3) Bone density baseline by 40-45 (earlier if risk factors), with serial monitoring around menopausal transition; (4) Comprehensive breast cancer risk assessment and individualized screening (consider supplemental MRI for high-risk patients); (5) Perimenopausal symptom management and informed MHT discussion; (6) Strength training — particularly important for women given the muscle and bone loss trajectory; aim for 2-4 sessions weekly with progressive overload; (7) Adequate protein (1.0-1.2 g/kg/day for adults over 40, higher for athletes and older women); (8) Cognitive longevity emphasis — women have higher Alzheimer's lifetime risk; (9) Pelvic floor and urogenital health attention often missed in standard care; (10) Mental health and social connection. Care is most effective when delivered by clinicians experienced in midlife women's health rather than generic adult longevity protocols.
Frequently Asked Questions
Is menopausal hormone therapy safe?
For most women initiating within 10 years of menopause or before age 60, transdermal estradiol with micronized progesterone (in women with a uterus) has a favorable risk-benefit for symptom relief, bone protection, and cardiovascular outcomes. Risk-benefit shifts unfavorably with later initiation, older oral preparations, and certain personal risk factors. Discuss with a clinician experienced in menopausal medicine.
When should I get a baseline bone density scan?
Age 40-45 for women with risk factors (low body weight, family history, early menopause, prior fracture, smoking, certain medications), and routinely by 50-65 depending on risk. Early baseline allows tracking through the rapid perimenopausal loss phase.
Why is heart disease underdiagnosed in women?
Symptoms are more often atypical, women present at older ages and with more comorbidities, traditional risk calculators historically underweighted female-specific factors, and women's cardiovascular research has been substantially underfunded. Awareness has improved but gaps remain.
How is longevity medicine different from gynecology?
Gynecology focuses on reproductive and pelvic health. Longevity medicine integrates that with cardiovascular, metabolic, musculoskeletal, cognitive, and cancer prevention across the lifespan. The best care often involves both specialists collaborating.
Get Help Now
Speak with a Haute MD Longevity Medicine physician
Dr. George Kaltner
CEO
Longevity Medicine · Miami Beach, FL
View Profile
Dr. Alexander Golberg
Longevity Medicine · New York, NY
View Profile
Dr. Steven Victor
Regenerative Medicine Specialist
Longevity Medicine · New York, NY
View ProfileAre you a Longevity Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · LONGEVITY MEDICINE
What Is Longevity Medicine for Men?
Longevity medicine for men addresses cardiovascular risk, testosterone, prostate health, and behavioral patterns that drive male healthspan and lifespan.
Read GuideGuide · LONGEVITY MEDICINE
What Is Longevity Medicine at 40?
Longevity medicine at 40 establishes baselines, identifies hidden cardiovascular and metabolic risk, and sets up two decades of optimal healthspan.
Read GuideGuide · LONGEVITY MEDICINE
What Is a Longevity Blood Panel?
A longevity blood panel goes far beyond a standard physical, measuring cardiovascular, metabolic, inflammatory, and hormonal markers that predict healthspan.
Read Guide